07:13am Monday 25 May 2020

Innovative Screening Method Uses RNA Interference Technology to Identify “Lethal” and “Rescuer” Genes

The ability to identify these genes in large-scale automated screening campaigns could lead to the discovery of valuable new drug targets. A genome-wide lethality screen that relies on RNA interference technology and led to the validation of 239 gene candidates essential for cell survival is described in ASSAY and Drug Development Technologies, a peer-reviewed journal published from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website.

A team of researchers led by Bhavneet Bhinder and Hakim Djaballah, Memorial Sloan-Kettering Cancer Center, New York, NY, present their work in the article “An Arrayed Genome-Scale Lentiviral-Enabled Short Hairpin RNA Screen Identifies Lethal and Rescuer Gene Candidates.”  

The authors developed a high-stringency analysis method used to determine which genes result in cell death when they are “knocked down.” Gene knockdown is achieved via an RNA interference approach, using double-stranded RNA molecules called short hairpin RNAs, or shRNAs. A shRNA binds to a target gene, blocking gene expression. The high-throughput screen is carried out in cells in 384-well microtiter plates.

About the Journal
Assay and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year in print and online. It provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a complementary sample issue may be viewed on the ASSAY and Drug Development Technologies website.

About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including OMICS: A Journal of Integrative Biology and Genetic Testing and Molecular Biomarkers.  Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Share on:

MORE FROM Medical Breakthroughs

Health news